Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.
Harris, P.A., Berger, S.B., Jeong, J.U., Nagilla, R., Bandyopadhyay, D., Campobasso, N., Capriotti, C.A., Cox, J.A., Dare, L., Dong, X., Eidam, P.M., Finger, J.N., Hoffman, S.J., Kang, J., Kasparcova, V., King, B.W., Lehr, R., Lan, Y., Leister, L.K., Lich, J.D., MacDonald, T.T., Miller, N.A., Ouellette, M.T., Pao, C.S., Rahman, A., Reilly, M.A., Rendina, A.R., Rivera, E.J., Schaeffer, M.C., Sehon, C.A., Singhaus, R.R., Sun, H.H., Swift, B.A., Totoritis, R.D., Vossenkamper, A., Ward, P., Wisnoski, D.D., Zhang, D., Marquis, R.W., Gough, P.J., Bertin, J.(2017) J Med Chem 60: 1247-1261
- PubMed: 28151659 
- DOI: https://doi.org/10.1021/acs.jmedchem.6b01751
- Primary Citation of Related Structures:  
5TX5 - PubMed Abstract: 
RIP1 regulates necroptosis and inflammation and may play an important role in contributing to a variety of human pathologies, including immune-mediated inflammatory diseases. Small-molecule inhibitors of RIP1 kinase that are suitable for advancement into the clinic have yet to be described ...